Alluvi, known as BI 4744, presents a promising development in obesity treatment. This dual activator targeting both GLP-1 and GIP targets demonstrates impressive efficacy in clinical assessments, possibly outperforming https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/